View in EDS

Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02.

Saved in:
Bibliographic Details
Title: Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02.
Authors: Hurvitz SA; Fred Hutchinson Cancer Center, University of Washington, Seattle, USA., Loi S; Peter MacCallum Cancer Centre, Melbourne, Australia., O'Shaughnessy J; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, USA., Okines AFC; The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK., Tolaney SM; Dana-Farber Cancer Institute, Boston, USA., Sohn J; Yonsei Cancer Center, Seoul, South Korea., Saura C; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Zhu X; Cross Cancer Institute, University of Alberta, Edmonton, Canada., Cameron D; Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK., Bachelot T; Centre Léon Bérard, Lyon, France., Hamilton E; Sarah Cannon Research Institute, Nashville, USA., Curigliano G; European Institute of Oncology, Milan, Italy; Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy., Wolff AC; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, USA., Harbeck N; Breast Center, Department of OB&GYN and CCC Munich, LMU University Hospital, Munich, Germany., Masuda N; Graduate School of Medicine, Kyoto University, Kyoto, Japan., Vahdat L; Dartmouth Health, Lebanon, USA., Zaman K; Lausanne University Hospital (CHUV), Lausanne, Switzerland., Valdes-Albini F; Sylvester Comprehensive Cancer Center, University of Miami, Coral Gables., Block M; Nebraska Cancer Specialists, Omaha, USA., Pluard T; Saint Luke's Cancer Institute, Kansas City, USA., Tan TJ; National Cancer Centre Singapore, Singapore., Gawryletz C; University of Colorado Health, Fort Collins, USA., Chan A; Breast Cancer Research Centre, Nedlands, Australia; Curtin University, Perth, Australia., Bedard PL; Princess Margaret Hospital, University Health Network, Toronto, Canada., Yerushalmi R; Rabin Medical Center, Petah Tikva, Israel; Tel Aviv University, Tel Aviv, Israel., Xu B; Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China., Schmitt M; Pfizer Inc., Bothell, USA., Xie D; Pfizer Inc., Bothell, USA., Borges VF; University of Colorado Cancer Center, Aurora, USA. Electronic address: virginia.borges@cuanschutz.edu.
Corporate Authors: HER2CLIMB-02 study investigators
Source: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2026 Mar; Vol. 37 (3), pp. 341-352. Date of Electronic Publication: 2025 Nov 17.
Publication Type: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41260264
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Hurvitz+SA%22">Hurvitz SA</searchLink>; Fred Hutchinson Cancer Center, University of Washington, Seattle, USA.<br /><searchLink fieldCode="AU" term="%22Loi+S%22">Loi S</searchLink>; Peter MacCallum Cancer Centre, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22O'Shaughnessy+J%22">O'Shaughnessy J</searchLink>; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, USA.<br /><searchLink fieldCode="AU" term="%22Okines+AFC%22">Okines AFC</searchLink>; The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK.<br /><searchLink fieldCode="AU" term="%22Tolaney+SM%22">Tolaney SM</searchLink>; Dana-Farber Cancer Institute, Boston, USA.<br /><searchLink fieldCode="AU" term="%22Sohn+J%22">Sohn J</searchLink>; Yonsei Cancer Center, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Saura+C%22">Saura C</searchLink>; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Zhu+X%22">Zhu X</searchLink>; Cross Cancer Institute, University of Alberta, Edmonton, Canada.<br /><searchLink fieldCode="AU" term="%22Cameron+D%22">Cameron D</searchLink>; Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK.<br /><searchLink fieldCode="AU" term="%22Bachelot+T%22">Bachelot T</searchLink>; Centre Léon Bérard, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Hamilton+E%22">Hamilton E</searchLink>; Sarah Cannon Research Institute, Nashville, USA.<br /><searchLink fieldCode="AU" term="%22Curigliano+G%22">Curigliano G</searchLink>; European Institute of Oncology, Milan, Italy; Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Wolff+AC%22">Wolff AC</searchLink>; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, USA.<br /><searchLink fieldCode="AU" term="%22Harbeck+N%22">Harbeck N</searchLink>; Breast Center, Department of OB&GYN and CCC Munich, LMU University Hospital, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Masuda+N%22">Masuda N</searchLink>; Graduate School of Medicine, Kyoto University, Kyoto, Japan.<br /><searchLink fieldCode="AU" term="%22Vahdat+L%22">Vahdat L</searchLink>; Dartmouth Health, Lebanon, USA.<br /><searchLink fieldCode="AU" term="%22Zaman+K%22">Zaman K</searchLink>; Lausanne University Hospital (CHUV), Lausanne, Switzerland.<br /><searchLink fieldCode="AU" term="%22Valdes-Albini+F%22">Valdes-Albini F</searchLink>; Sylvester Comprehensive Cancer Center, University of Miami, Coral Gables.<br /><searchLink fieldCode="AU" term="%22Block+M%22">Block M</searchLink>; Nebraska Cancer Specialists, Omaha, USA.<br /><searchLink fieldCode="AU" term="%22Pluard+T%22">Pluard T</searchLink>; Saint Luke's Cancer Institute, Kansas City, USA.<br /><searchLink fieldCode="AU" term="%22Tan+TJ%22">Tan TJ</searchLink>; National Cancer Centre Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Gawryletz+C%22">Gawryletz C</searchLink>; University of Colorado Health, Fort Collins, USA.<br /><searchLink fieldCode="AU" term="%22Chan+A%22">Chan A</searchLink>; Breast Cancer Research Centre, Nedlands, Australia; Curtin University, Perth, Australia.<br /><searchLink fieldCode="AU" term="%22Bedard+PL%22">Bedard PL</searchLink>; Princess Margaret Hospital, University Health Network, Toronto, Canada.<br /><searchLink fieldCode="AU" term="%22Yerushalmi+R%22">Yerushalmi R</searchLink>; Rabin Medical Center, Petah Tikva, Israel; Tel Aviv University, Tel Aviv, Israel.<br /><searchLink fieldCode="AU" term="%22Xu+B%22">Xu B</searchLink>; Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Schmitt+M%22">Schmitt M</searchLink>; Pfizer Inc., Bothell, USA.<br /><searchLink fieldCode="AU" term="%22Xie+D%22">Xie D</searchLink>; Pfizer Inc., Bothell, USA.<br /><searchLink fieldCode="AU" term="%22Borges+VF%22">Borges VF</searchLink>; University of Colorado Cancer Center, Aurora, USA. Electronic address: virginia.borges@cuanschutz.edu.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22HER2CLIMB-02+study+investigators%22">HER2CLIMB-02 study investigators</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229007735%22">Annals of oncology : official journal of the European Society for Medical Oncology</searchLink> [Ann Oncol] 2026 Mar; Vol. 37 (3), pp. 341-352. <i>Date of Electronic Publication: </i>2025 Nov 17.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9007735 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1569-8041 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209237534%22">09237534 </searchLink><i>NLM ISO Abbreviation: </i>Ann Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41260264
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.annonc.2025.11.005
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 341
    Titles:
      – TitleFull: Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Hurvitz SA
      – PersonEntity:
          Name:
            NameFull: Loi S
      – PersonEntity:
          Name:
            NameFull: O'Shaughnessy J
      – PersonEntity:
          Name:
            NameFull: Okines AFC
      – PersonEntity:
          Name:
            NameFull: Tolaney SM
      – PersonEntity:
          Name:
            NameFull: Sohn J
      – PersonEntity:
          Name:
            NameFull: Saura C
      – PersonEntity:
          Name:
            NameFull: Zhu X
      – PersonEntity:
          Name:
            NameFull: Cameron D
      – PersonEntity:
          Name:
            NameFull: Bachelot T
      – PersonEntity:
          Name:
            NameFull: Hamilton E
      – PersonEntity:
          Name:
            NameFull: Curigliano G
      – PersonEntity:
          Name:
            NameFull: Wolff AC
      – PersonEntity:
          Name:
            NameFull: Harbeck N
      – PersonEntity:
          Name:
            NameFull: Masuda N
      – PersonEntity:
          Name:
            NameFull: Vahdat L
      – PersonEntity:
          Name:
            NameFull: Zaman K
      – PersonEntity:
          Name:
            NameFull: Valdes-Albini F
      – PersonEntity:
          Name:
            NameFull: Block M
      – PersonEntity:
          Name:
            NameFull: Pluard T
      – PersonEntity:
          Name:
            NameFull: Tan TJ
      – PersonEntity:
          Name:
            NameFull: Gawryletz C
      – PersonEntity:
          Name:
            NameFull: Chan A
      – PersonEntity:
          Name:
            NameFull: Bedard PL
      – PersonEntity:
          Name:
            NameFull: Yerushalmi R
      – PersonEntity:
          Name:
            NameFull: Xu B
      – PersonEntity:
          Name:
            NameFull: Schmitt M
      – PersonEntity:
          Name:
            NameFull: Xie D
      – PersonEntity:
          Name:
            NameFull: Borges VF
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: 2026 Mar
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1569-8041
          Numbering:
            – Type: volume
              Value: 37
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Annals of oncology : official journal of the European Society for Medical Oncology
              Type: main
ResultId 1